What one share of Marker Therapeutics holds
We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker’s Multi Antigen Recognizing (“MAR”)-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications.
Marker Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.47 |
|---|---|
| Cash and investments | $0.68 |
| Book value | $0.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | — | −$239.63 | — | — | — | −$6.05 |
| 2015 | — | −$93.02 | — | — | — | −$36.31 |
| 2017 | $0.19 | −$11.62 | $0.00 | −$8.93 | — | $3.45 |
| 2018 | $0.11 | −$77.50 | $0.08 | −$7.66 | — | — |
| 2019 | $0.05 | −$4.70 | $0.08 | −$4.09 | — | $9.65 |
| 2020 | $0.11 | −$6.10 | — | — | — | $5.39 |
| 2021 | $0.00 | −$5.47 | — | — | — | $5.30 |
| 2022 | $0.42 | −$3.58 | — | — | — | $2.33 |
| 2023 | $0.38 | −$0.94 | — | — | — | $1.58 |
| 2024 | $0.73 | −$1.20 | — | — | — | $1.73 |
| 2025 | $0.23 | −$0.79 | — | — | — | $1.01 |
Common questions about Marker Therapeutics
How much does one share of Marker Therapeutics earn?
Over the last 12 months, Marker Therapeutics lost $0.47 for each share.
Does Marker Therapeutics pay a dividend?
Marker Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Marker Therapeutics’s book value per share?
Marker Therapeutics’s book value is $0.73 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Marker Therapeutics have?
Each share of Marker Therapeutics has $0.68 of cash and investments, as of June 30, 2026.
Has Marker Therapeutics bought back shares?
Marker Therapeutics’s share count rose about 11780% from 2014 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.